DARUNAVIR AND RALTEGRAVIR IN THE PLASMA OF HIV-INFECTED PATIENT: TDM AND PHARMACOKINETIC VARIABILITY

被引：0
|
作者：
De Simone, A.
Ragazzoni, E.
Di Giambenedetto, S.
Fabbiani, M.
Bracciale, L.
Colafigli, M.
Cauda, R.
De Luca, A.
Navarra, P.
机构：
[1] Univ Cattolica Sacro Cuore, Ist Farmacol, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Ist Clin Malattie Infett, Rome, Italy
来源：
INFECTION | 2009年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis
    Giguere, Pierre
    la Porte, Charles
    Zhang, Guijun
    Cameron, Bill
    [J]. AIDS, 2009, 23 (06) : 740 - 742
  • [2] Darunavir-Etravirine-Raltegravir as Salvage Combination Therapy in a Heavily Pretreated HIV-Infected Patient
    Vento, Sandro
    Vallone, Alfredo
    [J]. AIDS PATIENT CARE AND STDS, 2008, 22 (11) : 841 - 842
  • [3] Pharmacokinetics of Maraviroc, Raltegravir, Darunavir, and Etravirine in the Semen of HIV-Infected Men
    Antoniou, Tony
    Hasan, Sumaira
    Loutfy, Mona R.
    Kovacs, Colin
    Brunetta, Jason
    Smith, Graham
    Halpenny, Roberta
    La Porte, Charles
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (02) : E58 - E60
  • [4] Facial botryomycosis-like pyoderma in an HIV-infected patient: remission after initiation of darunavir and raltegravir
    Eyer-Silva, Walter de Araujo
    Rosa da Silva, Guilherme Almeida
    de Almeida Ferry, Fernando Raphael
    da Cunha Pinto, Jorge Francisco
    [J]. REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2017, 50 (02) : 277 - 279
  • [5] Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
    Jackson, Akil
    Watson, Victoria
    Back, David
    Khoo, Saye
    Liptrott, Neill
    Egan, Deidre
    Gedela, Keerti
    Higgs, Chris
    Abbas, Riaz
    Gazzard, Brian
    Boffito, Marta
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (05) : 450 - 457
  • [6] RALTEGRAVIR USE IN HIV-INFECTED PATIENTS
    Silvia Elena, Garcia-Ramos
    Garcia-Valdecasas Maria, Fernandez-Pacheco
    Perrin Rosario, Santolaya
    [J]. ATENCION FARMACEUTICA, 2011, 13 (04): : 244 - 244
  • [7] Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina
    Rombini, F.
    Cecchini, D. M.
    Uruena, A.
    Vecchio, C.
    Huberman, M.
    Cassetti, I.
    [J]. HIV MEDICINE, 2019, 20 : 66 - 66
  • [8] An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
    Hosoda, Tomohiro
    Uehara, Yuki
    Naito, Toshio
    [J]. INTERNAL MEDICINE, 2020, 59 (02) : 285 - 287
  • [9] Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
    Yamada, Eiko
    Takagi, Ritsuo
    Tanabe, Yoshinari
    Fujiwara, Hiroshi
    Hasegawa, Naoki
    Kato, Shingo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (07) : 567 - 570
  • [10] Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects
    Jackson, Akil
    Moyle, Graeme
    Dickinson, Laura
    Back, David
    Khoo, Saye
    Taylor, Jessica
    Gedela, Keerti
    Abongomera, George
    Gazzard, Brian
    Boffito, Marta
    [J]. ANTIVIRAL THERAPY, 2012, 17 (01) : 19 - 24
12345